A Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Bullous Pemphigoid With Disease Refractory to Oral Steroid Treatment

Trial Profile

A Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Bullous Pemphigoid With Disease Refractory to Oral Steroid Treatment

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Ligelizumab (Primary)
  • Indications Bullous pemphigoid
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 14 Oct 2015 Status changed from completed to discontinued as reported by the ClinicalTrials.gov record.
    • 14 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
    • 18 Jan 2015 Planned End Date changed from 1 Nov 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top